Studies of the interactions of antibodies with their Fc receptors, with a particular focus on the neonatal Fc receptor (FcRn) and its relationship with IgG and albumin. In addition, we are investigating how FcRn acts as a transporter in different cell types of the body. The studies will unravel the basic structural and cellular mechanisms that govern the functions of FcRn. Such knowledge offers opportunities for development of novel drug concepts that will secure improved half-life and biodistribution.
Studies of the mechanisms of infections at different body sites and how humoral immunity fights and restricts infection and virus replication. In particular, we are studying how antibodies contribute to protection against infectious diseases, and how FcRn and tripartite motif containing 21 (TRIM21) take part in cellular protection. Such knowledge can be utilized to develop novel antibody technologies tailored to combat infectious diseases.
Recent publications
Christopoulos PF, Gjølberg TT, Krüger S, Haraldsen G, Andersen JT, Sundlisæter E(2021) Targeting the Notch Signaling Pathway in Chronic Inflammatory Diseases Front Immunol, 12, 668207 DOI 10.3389/fimmu.2021.668207, PubMed 33912195
Azevedo C, Andersen JT, Traverso G, Sarmento B(2021) The potential of porcine ex vivo platform for intestinal permeability screening of FcRn-targeted drugs Eur J Pharm Biopharm, 162, 99-104 DOI 10.1016/j.ejpb.2021.03.009, PubMed 33771621
Mandrup OA, Ong SC, Lykkemark S, Dinesen A, Rudnik-Jansen I, Dagnæs-Hansen NF, Andersen JT, Alvarez-Vallina L, Howard KA(2021) Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity Commun Biol, 4(1), 310 DOI 10.1038/s42003-021-01790-2, PubMed 33686177